Georges Makhoul - Veru Director
| VERU Stock | USD 1.27 0.06 4.96% |
Director
Georges Makhoul is Director of Veru Inc since 2016.
| Tenure | 8 years |
| Address | 2916 North Miami Avenue, Miami, FL, United States, 33127 |
| Phone | 305 509 6897 |
| Web | https://verupharma.com |
Veru Management Efficiency
The company has return on total asset (ROA) of (0.5109) % which means that it has lost $0.5109 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2457) %, meaning that it created substantial loss on money invested by shareholders. Veru's management efficiency ratios could be used to measure how well Veru manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -2.33 in 2024. Return On Capital Employed is likely to gain to -2.64 in 2024. At this time, Veru's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 15.1 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 31.4 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Mark Saad | Axsome Therapeutics | 47 | |
| MB CPA | Axsome Therapeutics | N/A | |
| JeanPaul Kress | Sarepta Therapeutics | 49 | |
| Meryl Zausner | Seres Therapeutics | 61 | |
| Yodfat Buchris | Protalix Biotherapeutics | 44 | |
| Richard Barry | Sarepta Therapeutics | 59 | |
| Peter Donhauser | Anavex Life Sciences | N/A | |
| Gregory Behar | Seres Therapeutics | 48 | |
| Merrill McPeak | Iovance Biotherapeutics | 82 | |
| Roger Kornberg | Protalix Biotherapeutics | 68 | |
| Claude Nicaise | Sarepta Therapeutics | 65 | |
| Philippe Amouyal | Lexicon Pharmaceuticals | 59 | |
| Amos BarShalev | Protalix Biotherapeutics | 65 | |
| Werner Cautreels | Seres Therapeutics | N/A | |
| Myrtle Potter | Axsome Therapeutics | 59 | |
| Ryan Maynard | Iovance Biotherapeutics | 48 | |
| Mark Jacobson | Axsome Therapeutics | 41 | |
| Jay Moyes | Puma Biotechnology | 63 | |
| Mary Gray | Sarepta Therapeutics | 65 | |
| Judith Swain | Lexicon Pharmaceuticals | 69 | |
| Lorence Kim | Seres Therapeutics | 43 | |
Management Performance
| Return On Equity | -1.25 | ||||
| Return On Asset | -0.51 |
Veru Inc Leadership Team
Elected by the shareholders, the Veru's board of directors comprises two types of representatives: Veru inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Veru. The board's role is to monitor Veru's management team and ensure that shareholders' interests are well served. Veru's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Veru's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Haines, CFO, COO | ||
| Lucy Lu, Director | ||
| Gary Barnette, Chief Officer | ||
| Gary Bird, Executive Affairs | ||
| Jason Davies, Europe, UK | ||
| Philip JD, Executive Counsel | ||
| Mary Frank, Independent Director | ||
| FACS FACS, Pres Chairman | ||
| Martin Tayler, Executive Operations | ||
| Harry Fisch, Director | ||
| Georges Makhoul, Director | ||
| MD MBA, Chief Officer | ||
| Mario Eisenberger, Director | ||
| Overton Parrish, Vice Chairman of the Board | ||
| Samuel Fisch, Executive Communications | ||
| Domingo MD, Executive Operations | ||
| Mitchell Steiner, President CEO, Director | ||
| David Bethune, Independent Director | ||
| MD FACS, President Chairman | ||
| Michele Greco, CFO Officer | ||
| JD CPA, Executive Development | ||
| Joel Batten, Ex Franchise | ||
| Elgar Peerschke, Chairman of the Board | ||
| Michael Purvis, General VP |
Veru Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Veru a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.25 | ||||
| Return On Asset | -0.51 | ||||
| Operating Margin | (4.11) % | ||||
| Current Valuation | 159.63 M | ||||
| Shares Outstanding | 146.38 M | ||||
| Shares Owned By Insiders | 14.10 % | ||||
| Shares Owned By Institutions | 40.41 % | ||||
| Number Of Shares Shorted | 11.05 M | ||||
| Price To Earning | 240.00 X | ||||
| Price To Book | 4.28 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Veru Inc is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Veru Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Veru Inc Stock. Highlighted below are key reports to facilitate an investment decision about Veru Inc Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veru Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Veru Stock analysis
When running Veru's price analysis, check to measure Veru's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veru is operating at the current time. Most of Veru's value examination focuses on studying past and present price action to predict the probability of Veru's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veru's price. Additionally, you may evaluate how the addition of Veru to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
Is Veru's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Veru. If investors know Veru will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Veru listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.70) | Revenue Per Share 0.177 | Quarterly Revenue Growth (0.15) | Return On Assets (0.51) | Return On Equity (1.25) |
The market value of Veru Inc is measured differently than its book value, which is the value of Veru that is recorded on the company's balance sheet. Investors also form their own opinion of Veru's value that differs from its market value or its book value, called intrinsic value, which is Veru's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Veru's market value can be influenced by many factors that don't directly affect Veru's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Veru's value and its price as these two are different measures arrived at by different means. Investors typically determine if Veru is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Veru's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.